4.50Open4.50Pre Close0 Volume1 Open Interest5.00Strike Price0.00Turnover482.77%IV-17.25%PremiumMay 16, 2025Expiry Date6.48Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9312Delta0.0154Gamma1.68Leverage Ratio-0.0649Theta0.0009Rho1.56Eff Leverage0.0024Vega
Indivior Stock Discussion
Groundbreaking Study: New Treatment Option for Pregnant Women Battling Opioid Addiction Shows Promise
Game-Changing OUD Treatment Update: SUBLOCADE Now Offers 1-Hour Start Protocol
Unexpected FDA Delay: Indivior's SUBLOCADE Label Changes Face Setback Despite Clean Review
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance.
• Group now sees lower than expected Q3 2024 and FY 2024 SUBLOCADE net revenue (NR) from a combination of faster initial adoption among treatment providers of the...
No comment yet